The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Ki-67 proliferation index: the value of this tool in follicular lymphoma prognosis
In this video, Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Australia, shares insights into the prognostic significance of the Ki-67 proliferation index for patients with follicular lymphoma. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so with respect to follicular lymphoma, we currently really have a prognostication that involves mainly clinical findings or standard blood tests that patients have and imaging findings. We don’t really have a lot of robust validated biomarkers for follicular lymphoma to see whether they’re going to benefit from treatment or not. Our Ki-67 is obviously a measure of the activity or the proliferation of the tumor cells...
Yes, so with respect to follicular lymphoma, we currently really have a prognostication that involves mainly clinical findings or standard blood tests that patients have and imaging findings. We don’t really have a lot of robust validated biomarkers for follicular lymphoma to see whether they’re going to benefit from treatment or not. Our Ki-67 is obviously a measure of the activity or the proliferation of the tumor cells. And so we did a large National Lymphoma and Related Diseases Registry study, which is hosted by Monash University in Melbourne. And we looked at the prognostic significance. So if the Ki-67 is elevated, does this confer a worse prognosis in the modern era of treatment of follicular lymphoma and we certainly found from pathology reports that there is an association which was statistically significant. So we are now validating this in larger data sets and working with other registries around the world to ensure that this is relevant to other populations as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
